Genomics Bioscience & Technology Co Ltd

Genomics Bioscience & Technology Co Ltd has a basic and diluted share count of 72,448,000 shares, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company's profitability metrics are not available in the valuation snapshot, but analyst estimates suggest a challenging outlook, with a mean EPS estimate of -0.46 TWD and a mean EBIT estimate of -55,000,000 TWD. These figures indicate potential operational losses and a need for close monitoring of cost structures and revenue generation.

Segment and geographic exposure data are not disclosed in the available information, making it difficult to assess revenue concentration or geographic diversification. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to regional or market-specific factors.

The company's growth trajectory appears uncertain, with the last actual revenue at 708,375,000 TWD and a mean revenue estimate of 832,000,000 TWD for the current fiscal year. While the estimate suggests a potential increase, the magnitude and sustainability of this growth remain unverified without further financial disclosures.

Risk factors include the inability to assess liquidity risk and the potential for operational losses, as reflected in the negative EPS and EBIT estimates. The dilution risk is currently low, but the absence of detailed capital structure data limits the ability to fully evaluate long-term financial health.

Recent events and filings have not been disclosed in the available data, which limits the ability to assess any material developments that could impact the company's operations or financial position.

Revenue TWD 708.4M, +36,9% YoY; Operating income +43,6% YoY.

• ▍Revenue TWD 708.4M, +36,9% YoY
• ▍Operating income +43,6% YoY
• ▍Net income +82,3% YoY
• ▍Free cash flow +79,0% YoY
• ▍Net margin -5.6%